Qube Research & Technologies LTD Leap Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.96 - $1.91 $34,796 - $69,229	-36,246 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$1.6 - $3.35 $57,993 - $121,424	36,246 New	36,246 $63,000
Q2 2021 Aug 13, 2021	SELL	$1.48 - $1.92 $33,086 - $42,923	-22,356 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$1.82 - $3.01 $164,691 - $272,374	-90,490 Reduced 80.19%	22,356 $42,000
Q4 2020 Feb 16, 2021	SELL	$1.49 - $2.37 $191,867 - $305,184	-128,770 Reduced 53.3%	112,846 $254,000

Q3 2020 Nov 12, 2020	BUY	$1.68 - $2.17 $320,070 - $413,424	190,518 Added 372.85%	241,616 $478,000
Q2 2020 Aug 14, 2020	BUY	$1.39 - $2.84 $71,026 - $145,118	51,098 New	51,098 $107,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $194M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.